MASH discovery redefines subtypes with distinct risks: Findings could shape future of fatty liver disease treatment
December 9, 2024 / MASH Subtypes Discovery / Precision Medicine for MASH / Cardiometabolic Liver Disease / Fatty Liver Treatments / MASLD Subtypes Diagnostics
MASH (metabolic dysfunction-associated steatohepatitis) comprises two distinct subtypes: liver-specific, with rapid liver disease progression but low cardiovascular risk, and cardiometabolic, with higher diabetes and cardiovascular risks. These findings enable precision diagnostics and tailored treatments for improved outcomes.
Denifanstat Associated With MASH Resolution, Improves Histological Features
December 9, 2024 / Denifanstat and MASH Resolution / Fatty Acid Synthase Inhibitor Therapy / MASH Fibrosis Improvement / Metabolic Liver Disease Treatment
Denifanstat, a fatty acid synthase inhibitor, significantly improved histological features, resolved MASH, and reduced fibrosis in patients with F2–F3 fibrosis. This phase 2b trial supports further development for advanced-stage metabolic liver disease treatment.
Can HIIT’s metabolic benefits last? New study explores post-exercise sustainability in diabetes
December 9, 2024 / HIIT and Metabolic Benefits / Insulin Sensitivity in T2D / Mitochondrial Function / Exercise Training
HIIT improves insulin sensitivity, mitochondrial function, and VO2 max in individuals with and without T2D, with some benefits persisting post-detraining. Sustained improvements include glycemia and hepatic health in insulin-resistant individuals, potentially mediated by SEV protein release.
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
December 9, 2024 / MASLD Polygenic Risk Scores / Liver-specific MASLD Subtype / Cardiometabolic MASLD Risks / Liver Disease
Partitioned polygenic risk scores identify two MASLD subtypes: a liver-specific type, driven by triglyceride retention, with rapid liver disease progression and low cardiovascular risk, and a systemic type linked to cardiometabolic syndrome. Findings advance precision medicine for MASLD.
New research reveals two types of fatty liver disease
December 9, 2024 / MASLD Liver-Specific Subtype / Fatty Liver Disease Risks / MASLD / Genetic Variants in Fatty Liver / MASLD Cardio-renal-metabolic Link
Two MASLD subtypes—liver-specific (aggressive, liver-focused) and systemic (linked to cardio-renal-metabolic syndrome)—have been identified using genetic analyses. These findings enable tailored diagnostics and treatments, advancing precision medicine for liver disease and its associated risks.
U-shaped association seen for alcohol consumption, cardiometabolic disease
December 6, 2024 / Alcohol / Cardiometabolic Risk / Coronary Heart Disease / Alcohol Impact on Type 2 Diabetes
A U-shaped relationship exists between alcohol consumption and coronary heart disease (CHD) and type 2 diabetes (T2D) risk, but Mendelian randomization analyses show no causal link, suggesting no cardiometabolic benefits from moderate alcohol consumption.
Local student shares awareness of PKU metabolic disorder
December 6, 2024 / PKU Metabolic Disorder Awareness / Medical Nurtrition Equity Act / PKU Medical Food Coverage / Rare Metabolic Disorder Support
High school student Claire Oliver raises awareness about phenylketonuria (PKU), a rare metabolic disorder, advocating for the Medical Nutrition Equity Act to ensure insurance coverage for essential medical foods and formulas critical for PKU management.
Replacing carbohydrates with protein and fat improves cholesterol profiles in type 2 diabetes
December 5, 2024 / High-protein Diet and T2D / Carbohydrate Reduction Cholesterol Benefits / Diabetes
A carbohydrate-reduced, high-protein diet improves cholesterol profiles in type 2 diabetes by reducing atherogenic lipoproteins, enhancing HDL, and lowering intrahepatic triglycerides, offering benefits beyond weight loss compared to conventional diabetes diets.
Disrupted sleep-wake rhythms linked to liver disease progression
December 4, 2024 / MASLD / Sleep Disruption / Circadian Rhythm Liver Disease / Metabolic Disorders / MASLD / Obesity-linked Liver Dysfunction
Disrupted sleep-wake rhythms exacerbate MASLD progression, marked by increased nighttime awakenings and daytime sleep. Objective actigraphy highlights fragmentation as a potential contributor to MASLD pathogenesis, emphasizing the need for sustained sleep interventions alongside metabolic management strategies.
Eating Dark Chocolate May Help Lower Your Risk of Type 2 Diabetes
December 4, 2024 / Dark Chocolate Diabetes Benefits / Cocoa Polyphenols Insulin Sensitivity
Dark chocolate consumption (≥70% cocoa) reduces type 2 diabetes risk by improving insulin sensitivity and lowering oxidative stress, unlike milk chocolate, which is linked to weight gain. Moderation and overall healthy lifestyle habits remain essential for diabetes prevention.
Cancer therapy may raise heart attack and stroke risks by disrupting immune regulation in arteries
December 4, 2024 / Immune Checkpoints and Atherosclerosis / Cardiovascular Inflammation / Cancer Therapy Heart Risks
Immune checkpoint molecules like PD-L1 and CTLA4 are highly expressed in atherosclerotic plaques, mediating inflammation and immune interactions. Cancer therapies targeting these pathways may inadvertently increase cardiovascular risks, including heart attack and stroke.
ACMG sets new lifelong guidelines for managing phenylalanine hydroxylase deficiency
December 4, 2024 / PAH Deficiency Lifelong Management / Neurocognitive Outcomes in PAH Deficiency
The ACMG updated lifelong PAH deficiency management guidelines, emphasizing maintaining blood phenylalanine (Phe) levels ≤360 μmol/L for optimal neurocognitive outcomes and recommending maternal Phe control before and during pregnancy to prevent adverse fetal effects.
Cold acclimation with shivering improves metabolic health in adults with overweight or obesity
December 3, 2024 / Cold Acclimation Therapy / Shivering / Metabolic Health / Insulin Sensitivity Improvement / Glucose Tolerance / Metabolic Disorders
Cold acclimation with shivering enhances insulin sensitivity, improves glucose tolerance, and lowers fasting glucose, triglycerides, fatty acids, and blood pressure in adults with obesity or impaired glucose tolerance, offering a potential alternative for metabolic health improvement.
Fas-p53 pathway drives metabolic dysfunction and obesity-linked insulin resistance
December 3, 2024 / Fas-p53 Pathway / Obesity Insulin Resistance / Therapeutic Targets in Obesity
The Fas-p53 pathway in adipocytes impairs metabolic function, reduces energy expenditure, and worsens obesity-linked insulin resistance, suggesting it as a therapeutic target for improving energy metabolism and reducing inflammation in obesity-related disorders.
Holistic lifestyle interventions outshine drugs in preventing cardiometabolic diseases
December 3, 2024 / Cardiometabolic Disease Prevention / Obesity / CMD Risk Reduction / Sustainable Health Interventionss
Combined lifestyle interventions (CLIs) outperform drugs in preventing cardiometabolic diseases by improving glycemic control, body weight, and CMD risk factors. Long-term benefits are amplified by population-level policies promoting healthy behaviors and equitable access to interventions.
How carrageenan affects insulin resistance
December 3, 2024 / Carrageenan Insulin Resistance / Gut Inflammation and BMI / Food Additives / Gut Health
Carrageenan consumption induces gut permeability, inflammation, and insulin resistance in overweight individuals, potentially exacerbating metabolic dysfunction. Effects may depend on BMI, suggesting long-term risks in high-risk populations warrant further investigation.
Study finds no impact of high vitamin D doses on type 2 diabetes prevention
December 3, 2024 / Vitamin D / Diabetes Prevention / Type 2 Diabetes Risk Factors / Vitamin D Prediabetes Impact
Long-term use of high-dose vitamin D supplementation does not reduce type 2 diabetes risk in individuals without prediabetes but with sufficient baseline vitamin D levels, as shown by the Finnish Vitamin D Trial (FIND).
An affordable and effective nutritional approach to help reduce inflammation and prevent type 2 diabetes
December 3, 2024 / Omega-3 Inflammation Reduction / LDL and Adipose Tissue Health / Type 2 Diabetes Prevention Nutrition / Cardiometabolic Benefits / Metabolic Health
Marine omega-3 supplementation reduces adipose tissue inflammation linked to high LDL, improves carbohydrate and fat metabolism, and lowers type 2 diabetes and cardiovascular disease risks, offering an affordable approach to address cardiometabolic health challenges.
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline
December 3, 2024 / Maze Therapeutics Precision Medicine / APOL1 Inhibitor Kidney Therapy / Series D Biopharma Funding
Maze Therapeutics secured $115M in Series D funding to advance MZE829, an APOL1 inhibitor for kidney disease, and MZE782, an SCL6A19 inhibitor targeting chronic kidney disease and phenylketonuria, supporting its precision medicine platform and clinical programs.